What is Melanotan II?

Melanotan II (Melanotan II (cyclic α-MSH analog)) is a Non-selective melanocortin receptor agonist. Synthetic cyclic α-MSH analog with non-selective activity across MC1, MC3, MC4, and MC5 receptors. It is researched for rapid skin darkening, appetite suppression, erectile function enhancement, increased libido.

What is the recommended Melanotan II dosage?

Common dosages: 250-500 mcg per injection administered every other day via subcutaneous injection. Cycle length: 2-4 weeks for tanning effects. Half-life: not precisely established; effects persist longer than MT-I.

What are the side effects of Melanotan II?

Extensive adverse effects: nausea, vomiting, facial flushing, involuntary erections, yawning, loss of appetite. Serious reports of rhabdomyolysis, renal infarction, posterior reversible encephalopathy syndrome, and sympathomimetic toxicity. Increased melanoma risk, atypical moles, melanonychia (nail darkening). Dose-dependent toxicity.

Is Melanotan II safe?

Melanotan II has shown a preliminary safety profile in research. Not FDA-approved. Banned for human use in many jurisdictions. Warnings issued by US FDA, UK MHRA, and other health agencies. WADA banned. All research should follow appropriate safety protocols.

Melanotan II Dangerous Mole Changes: ABCDE Warning Signs Guide: Recommended Protocol & Cycle Length

Medical Disclaimer

For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.

Melanotan II accelerates mole darkening and can create new mole-like lesions, requiring vigilant monitoring. ABCDE warning signs: Asymmetry, irregular Borders, Color variation, Diameter >6mm, and Evolution (rapid change). Photograph existing moles pre-cycle, perform monthly self-checks, and report ABCDE changes to dermatologist immediately.

Understanding Melanotan II's Mole Response Mechanism

Melanotan II accelerates mole darkening and creates new pigmented lesions within 2-4 weeks of starting cycle. Mechanism: increased melanin production stimulates transport to existing pigmented lesions and activates dormant melanocytes creating new lesions. Extent of change varies dramatically—some users see minimal mole response, others see pronounced darkening. Concern: does accelerated change increase malignant transformation risk? Unknown, but caution warranted and monitoring essential.

ABCDE Criteria: Identifying Atypical Changes

ABCDE guideline for suspicious moles: Asymmetry (one half unlike other), Borders (irregular, scalloped, notched), Color (multiple colors within lesion), Diameter (>6mm), Evolution (rapid change). Rapid evolution during Melanotan II cycling is particularly concerning—changes occurring over weeks vs months warrant dermatology evaluation. Even benign mole darkening should be photographed and monitored for concerning ABCDE changes.

Pre-Cycle Dermatology Documentation and Baseline

Essential: photograph all existing moles with date/time stamps before starting Melanotan II cycle. Professional dermatology evaluation establishing baseline recommended, especially with personal/family melanoma history or dysplastic nevi. Baseline photographs enable objective comparison for suspicious changes. Monthly self-photos during cycle aid change detection and documentation.

Monitoring Protocol: Self-Checks and Professional Follow-Up

Monthly self-inspection: compare current photos to baseline, assess for changes in size, color, symmetry. Immediate dermatology if ABCDE criteria met. Annual professional dermatology evaluation recommended. Some experts suggest baseline + mid-cycle dermatology during Melanotan II use due to accelerated mole changes. Professional monitoring provides peace of mind and early detection if concerning changes emerge.

Frequently Asked Questions

Does Melanotan II darken existing moles?

Yes. Most users report deepened pigmentation in existing moles during cycling.

Can it create new moles?

Can create new pigmented lesions resembling moles. Usually benign but warrant evaluation.

What changes are concerning and require immediate dermatology?

Asymmetric, irregular-bordered, multi-colored lesions >6mm growing rapidly warrant immediate evaluation.

Should I get baseline photos before starting?

Absolutely essential. Photograph all moles pre-cycle with date/time for objective comparison.

How often should I perform self-checks?

Monthly self-inspection. Dermatology immediately if ABCDE criteria noted.

Is baseline dermatology evaluation necessary?

Highly recommended, especially with personal/family melanoma history or dysplastic nevi.